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Objectives: The treatment for recurrent thymoma remains a very 
controversial issue. This study aims to investigate the long-term out-
comes in patients with relapse according to treatment strategies and 
clinicopathological features.
Methods: We retrospectively analyzed the database of three tertiary cen-
ters of thoracic surgery with the aim of reviewing the clinical records of 
81 patients who experienced a recurrent thymoma after radical thymec-
tomy, in the period between January 2001 and June 2013. The staging of 
both primitive and recurrent thymomas were based on the surgical and 
pathological criteria described by Masaoka. Experienced pathologists 
reassessed independently the histology of the initial thymoma and its 
relapse, according to the WHO classification. To the purposes of this 
study R+ resection or thymic carcinoma were considered as exclusion 
criteria. The overall outcome for long-term (5 years and 10 years) sur-
vival and disease-free survival after initial thymectomy and after treat-
ment of recurrent thymoma were analyzed using standard statistics.
Results: The population was gender balanced (41 M, 40 F), mean 
age: 46.4 ± 12.3 years. Fifty-four patients (66.7%) were affected by 
myasthenia gravis, while the other 14 by other paraneoplastic con-
ditions. Surgery was performed in 61 patients (75.3%,), and radio-
therapy and/or chemotherapy in 14 patients (17.3%). The mean 
follow-up duration after recurrence onset was 66.3 ± 56.4 months. 
Adjuvant therapy had no effect on prolonging the disease-free sur-
vival: no differences were found when investigating the administra-
tion of adjuvant chemotherapy (no CHT = 91.5 ± 76.4 months versus 
yes CHT=64.0 ± 41.3) and radiotherapy (no RT=86.2 ± 72.8 months 
versus yes RT= 93.0 ± 62.3; p = 0.8). Relapses were mostly local 
(mediastinum: 15 cases, pleura: 44 cases); hematogenous distant 
recurrences were observed in 15 cases (lung: 12; liver: 1; bone: 2 
cases). An upgrade in the WHO class (defined as the “migration” 
of WHO class at initial thymectomy to more aggressive WHO class 
assigned at thymic recurrence resection) was found in 25/61 cases 
(40.9%), but this phenomenon apparently did not influence patient’s 
prognosis. Overall, the 5- and 10-year survival rates after the initial 
thymectomy were 94.8% and 71.7%, respectively, while the 5- and 
10-year survival rates after the treatment of the recurrence at the 
thymic level were 73.6% and 48.3%, respectively (82.4% at 5 years 
and 65.4% at 10 years when a R0-re-resection was obtained). The 
analysis on the trends of disease-free survival indicated that the site 
of recurrence (hematogenous diffusion) seems to be associated to a 
higher risk of re-relapse (p = 0.01).
Conclusions: Even following a thymectomy performed with radical 
intent, thymoma may recur several years later, usually as a locore-
gional relapse. A rewarding long-term survival may be expected 
after treatment, especially when a re-resection (radical) is performed 
(82.4% at 5 years). An histopathological “WHO upgrade” (from 
“low-risk” WHO classes at thymectomy to “high-risk classes” at 
relapse) may be observed in a remarkable percentage of patients 
(nearly 40% in this series), but this phenomenon seems to be not cor-
related with any worsening of the prognosis.
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Thymoma is a rare epithelial tumor of the anterior medias-tinum and its incidence is nearly 0.15 cases per 100,000 
population per year1; it has an indolent behavior and its recur-
rence may occur many years after a radical resection (R0) and 
with a relapse rate ranging between 10% and 30% after the 
first complete resection.2–4 Thymoma recurrences often appear 
as locoregional rather than hematogenous (distant) and these 
involve mostly the anterior mediastinum, the pericardium, the 
pleural space or the surface of the pulmonary parenchyma—
visceral pleura—adjacent to the thymoma. As well, an intratho-
racic onset is frequently observed (parietal pleura). The distant 
metastatic spread involves the pulmonary parenchyma in the 
large majority of cases while other organs are usually spared.5
Because of its low incidence and recurrence rates, the 
most recent important reports concerning the issue of thymic 
recurrence after resection for thymoma are based on single-
center observational studies with small cohorts: to date, due 
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to the very same reasons, the treatment strategies are not yet 
completely standardized and no consensus has yet been estab-
lished among the spectrum of treatment options.
Several authors6–8 have recommended a surgical 
approach, whenever possible, in case of recurrence of thymic 
tumors, reporting good long-term survivals (LTSs) even after 
iterative surgery.9 Contrarywise, other authors support and 
recommend chemotherapy and radiotherapy alone.10–12
We herein report the results of a multicenter study inves-
tigating the long-term outcomes of patients who experienced a 
recurrence after initial R0-resection for thymoma.
This multicenter study has gathered data from three high 
volume hospitals, aiming to clarify some controversies: the 
long-term outcomes (LTS and Disease-Free Interval [DFI]) 
were evaluated as stratified according to treatment modalities 
and by matching the outcomes with clinical and pathological 
features of the thymoma at the time of diagnosis.
MATERIALS AND METHODS
The Institutional Review Board approval was prelimi-
narily obtained for research using data derived from standard 
clinical practice with no experimental interventions applied.
In order to gather a consistently homogeneous population 
to run this study, cases were collected from three high-volume 
thoracic surgery centers with homogeneous clinical practice 
and significant experience in thymic neoplasms (Department 
of Thoracic Surgery, University of Torino; Department of 
Thoracic Surgery, Catholic University of Rome; Department 
of Thoracic Surgery, Groupe Hospitalier Cochin Hôtel-Dieu, 
AP-HP, Université Paris Descartes, Paris). The analysis was 
focused on 81 patients with thymoma initially treated with 
complete tumor resection, and then presented with dis-
ease recurrence during the follow-up, in the period between 
January 2001 and June 2013.
Definition of recurrence was assumed after a complete 
resection only, according to ITMIG definitions.5 Patients who 
underwent incomplete resection of the initial thymoma and 
those initially affected by thymic carcinoma were excluded 
from this study. The analysis comprised relapses of thymic 
carcinoma developed from thymoma because of histological 
upgrade.
Population was investigated by reviewing the clini-
cal presentation, histopathological characteristics, treatment 
modalities, LTS, and disease-free survival (DFS) results.
Clinical and pathological data (e.g., gender, age, pres-
ence of myasthenia gravis [MG], operative notes of the 
primitive thymoma and recurrence procedures, postoperative 
complications, pathological issues, postoperative therapy, pat-
terns of recurrence, and long-term follow-up information) 
were retrospectively retrieved. Initial thymoma staging was 
based on the surgical and pathological criteria as described 
by Masaoka.13 The histological description of both the initial 
thymoma and the relapse of disease were independently reas-
sessed and reclassified according to WHO classification14 by 
experienced pathologists.
The treatment of the relapsed tumor varied accord-
ing to its extent, MG control, and patient general condition. 
Evidently, the different choice of treatment according to 
nonstandardized/nonvalidated criteria represents an important 
limitation, but we believe this kind of bias to be intrinsic of the 
study strategy, and thus not avoidable.
At the time of the initial resection, an extended thy-
mectomy was performed in all patients (with a substantially 
comparable surgical technique in all three centers). After that, 
all subjects were monitored with a long-time clinical and 
radiological follow-up considering the possibility of a tardive 
recurrence after thymectomy. An 18F-FDG positron emission 
tomography–computed tomography scan evaluation and even-
tually fine-needle aspiration biopsy or surgical biopsy were 
indicated in all lesions suspected to be a recurrence at com-
puted tomography scan.
Longitudinal resternotomy was the access of choice in 
case of mediastinal recurrence. In case of pleural recurrence, 
a thoracotomic approach was preferred.
All interventions were performed with radical intent. 
Eventually, induction chemotherapy was planned to increase 
surgical resectability when indicated (depending on the deci-
sions of a Multidisciplinary Board). A discrete metastasectomy 
was performed in patients with single or few localizations. In 
case of a massive pleural spread finding, pleurectomy was 
indicated (if technically feasible and patient clinical “fit for 
surgery”) to achieve a macroscopic radical resection; other-
wise, patients judged “unfit for surgery” were directed to mul-
timodal treatments such as chemotherapy and/or radiotherapy. 
Finally, radiotherapy was adopted in case of incomplete surgi-
cal resection.
Short- and long-term results in each group were ana-
lyzed and reported along with postoperative mortality and 
morbidity rates. Long-term results were analyzed in terms of 
LTS and DFS and factors with a potential of impacting the 
predictivity toward prognosis were assessed.
Statistical Analysis
The t test, the ANOVA, the chi-square test, or the 
Fisher’s exact tests were used where appropriate. The overall 
LTS (including noncancer-related deaths) and the DFS were 
calculated by the Kaplan–Meier method and compared by the 
log-rank test.
The interval from thymectomy to the recurrence (DFI) 
was defined as the period from the first operation to the diag-
nosis of recurrence and reported as a continuous variable.
The follow-up on LTS was defined as the period between 
the diagnosis of relapse and the last contact or death, while the 
follow-up of DFS was calculated from treatment of recurrence 
to the second recurrence.
The following variables were considered: type of treat-
ment, age, gender, presence of MG, initial WHO classifica-
tion, initial Masaoka classification, DFI, site of recurrence, 
number of sites involved, type of treatment, completeness of 
resection, and histological upgrading. All the variables show-
ing a possible association with survival (p < 0.10) were entered 
in a multivariate analysis (Cox proportional hazard model) to 
identify independent prognostic factors.
To avoid the bias of patients with extrathoracic relapses, 
a further analysis was performed including patients with intra-
thoracic disease only. SPSS release 16.0 was used to perform 
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all statistical analysis. Results were considered significant if 
the p value was <0.05.
RESULTS
The male/female ratio was 40/41; mean ages at the time 
of the original operation and at the moment of relapse onset 
were 46.4 ± 12.3 years and 53.14 ± 13.8, respectively.
The Masaoka staging assessment of the initial thymoma 
consisted of four patients in stage I, 13 in stage II, 32 in stage 
III, and 30 in stage-IVa (two clinical records missing).
Main demographics, clinical and pathological charac-
teristic at the moment of the initial resection are illustrated in 
Table 1. In particular, 54 patients (66.7%) were affected by 
MG and no postoperative onset of myasthenia was observed 
in the overall population, while in 14 patients, other paraneo-
plastic conditions (sometimes more than one for patient) were 
observed as follows: autoimmune thyreopathy (10 cases), 
vitiligo (2 cases), systemic lupus erythematosus, Good’s syn-
drome, nephrotic syndrome, autoimmune hemolytic anemia, 
autoimmune hypogammaglobulinemia, neuromyotonia, and 
other cognitive disease (one case for each condition).
Recurrence Patterns and Re-resections
The mean DFI, defined as the period from thymectomy 
to the diagnosis of recurrence, was 86.5 ± 72.1 months. The 
time of onset of the first recurrence was not statistically differ-
ent among patients when stratifying for Masaoka classification 
(mean ± SD of DFI months: I = 55.7 ± 37.3; II = 125.9 ± 110.7; 
III = 68.2 ± 55.3; VIa = 84.7 ± 63.0 p = 0.08) and WHO 
classification (mean ± SD of DFI months: A = 52.5 ± 0.7; 
AB = 99.0 ± 56.5; B1 = 106.13 ± 95.3; B2 = 98.5 ± 78.2 
B3 = 67.3 ± 60.1; p = 0.41). The use of adjuvant therapy had 
no effect on prolonging the DFI; indeed, no differences were 
found comparing means of DFI according to adjuvant chemo-
therapy (no = 91.5 ± 76.4 versus yes = 64.0 ± 41.3) and radio-
therapy (no = 86.2 ± 72.8 versus yes = 93.0 ± 62.3; p = 0.8).
The pattern of relapse pattern (recurrence site) is 
described in Table 1. The most common site of relapse was 
locoregional (mediastinum and pleura in 15 and 44 cases, 
respectively). On the other hand, hematogenous distant recur-
rences were observed at the level of the lung (12 cases), liver 
(one case), and bone (two cases).
Surgery was performed in 61 patients (75.3%,), while 
other treatments (radiotherapy and chemotherapy) were 
accomplished in 20 (24.6%). Because of their poor general 
condition, two patients (2.5%) were supported with palliative 
care alone.
Surgical resections were distributed as follows: 12/15 
mediastinum, 36/47 pleura, 11/3 pulmonary, and 2/6 other 
sites.
Presumably, a complete resection of the recurrent tumor 
was obtained in 45 cases (73%). The remaining patients under-
went a subtotal resection (“debulking resection”) because of 
the extent of the recurrence, which was judged as nonradically 
resectable disease only. Postoperative mortality was nil, whereas 
postoperative complications occurred in 19 patients (26.2%).
Interestingly, a histological “upgrading” (defined as 
the migration of the assigned WHO class at the moment of 
initial diagnosis of thymoma to the WHO class assigned at the 
moment of thymic recurrence resection) was found in 25/61 
cases (about 40.9%) as reported in Table 1.
Long-Term Results
The mean follow-up duration was 66.3 ± 56.4 months. 
Overall 5- and 10-year survival rates from initial thymectomy 
of the whole analyzed population were 94.8% and 71.7%, 
respectively.
On the other hand, the 5- and 10-year survival after 
recurrent thymoma treatment (Table 2) were superior when 
a complete re-resection was obtained (even if statistical sig-
nificance was not reached) and in patients with B2 and B3 
histotypes (p = 0.03). Despite some prognostic correlations 
identified with the log-rank test (see Table 2), results from 
Cox regression analysis suggested that surgical treatment, 
completeness of resection, and WHO status (either WHO thy-
moma and WHO relapse) were not independent risk factors 
for death (Figs. 1 and 2.).
The DFS analysis by the Kaplan–Meier method, 
according to each independent variable (Table 3), has 
shown that the site of recurrences (hematogenous 
 diffusion) seems correlated to a high risk of re-relapses 
(p = 0.01). Conversely, the histological WHO upgrading 
is not significantly correlated with a worse prognosis in 
terms of LTS and DFS (Table 4).
Intrathoracic Disease Long-Term Results
Overall 5- and 10-year survival rates from recurrence of 
patients with intrathoracic recurrence were 70.6% and 56.0%, 
respectively.
Among the group of patients subjected to surgical ther-
apy, consisting of 62 patients, 5- and 10-years survival rates 
were 61.5% and 52.7%, respectively, while that of patients 
who underwent chemo/radiotherapy treatment were 72.4% 
and 55.7%, respectively (p = 0.12). On the other hand, the 5- 
and 10-years survival rate after complete resection of relapse 
were 84.5% and 64.2%, respectively, whereas for R+ patients, 
these were 56.3% (5 years) and 56.3 (10 years) (p = 0.33). No 
further differences were found regarding histological upgrade 
(p = 0.26) or site of recurrence (mediastinal versus pleural) 
(p = 0.66) and MG (p = 0.57).
The DFS analysis by the Kaplan–Meier method showed 
a 5- and 10-year DFS of 74.4% and 48.1%, respectively. 
According to each independent variable, the log-rank test 
has shown that the mediastinal site of recurrence had a better 
5- and 10-year DFS (100% and 57.1%) than pleural spread 
recurrences (65.9% and 45.8%; p = 0.11).
No further variables seem related to a high risk of re-
relapses, neither histological WHO upgrading (p = 0.67),nor 
MG (p = 0.59).
DISCUSSION
Thymomas rarely recur after radical resection with 
a relapse rate ranging from 10% to 30% in the major series 
published.5 Commonly, a relapse of the disease may be 
observed even several years after the primary thymectomy.7 
In this study, we report a DFI of nearly 8 years (Table 1). This 
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observation confirms not only the relative indolent but also 
the insidious behavior of this disease, and accordingly, the 
need of long-term surveillance (more than 10 years) after a 
complete thymoma resection.15 Recurrences usually spread 
in the bed of the primitive tumor (mediastinal relapse) or 
involve the pleural spaces, while distant metastases are only 
rarely detected.16 Our series confirm this pattern of relapse, 
with the mediastinum and pleura being the most common sites 
of relapse (59 patients, 72.8%); hematogenous extrathoracic 
metastases occurred in few cases (three patients, 3.7%).
TABLE 1.  Patients Clinical Pathological and Surgical Characteristics
No or Mean Percentage or Range
All population 81
Sex male 40 49.4
Age at thymectomy (years) 46.4 ± 12.3 46(16–75) Median (range)
Time from thymectomy (months) 148.7 ± 84.3 136 (12–423) Median (range)
Myasthenia gravis 54 66.7
Paraneoplastic syndrome other than myasthenia gravis 14 17.3
Neo-adjuvant RT 3 3.7
Neo-adjuvant CT 13 16.0
Masaoka initial stage
  I 4 4.9
  II 13 16.0
  III 32 39.5
  IV 30 37.0
  Missing 2 2.5
Initial WHO histological classification
  A 2 2.5
  AB 4 4.9
  B1 12 14.8
  B2 35 43.2
  B3 28 34.6
Adjuvant CT 21 25.9
Adjuvant RT 49 60.5
Recurrence
  Disease-free interval (from thymectomy to recurrence) 86.5 ± 72.1 86 (8–390) Median (range)
  Disease-free interval (from diagnosis of recurrence) 66.3 ± 56.4 62 (0–270) Median (range)
Treatment
  Surgery 61 75.3
  Chemo/radiotherapy alone 14 17.3
  None 2 2.5
  Missing 4 4.9
  Pre- or postoperative chemo/radiotherapy 15 18.5
Resection
  Incomplete 16/61 16.0
Site of recurrence
  Mediastinum 15 18.5
  Pleura/pericardium 47 58.0
  Lung 13 16.0
  Other site 6 7.4
Recurrence WHO histological classification (operated patients only)
  B1 4 6.6
  B2 24 39.3
  B3 25 41.0
  B3/C 8 13.1
Second recurrence (surgical patient) 23/61 37.7
Third recurrence or more 8/61 11.4
WHO upgrade (surgical patient) 25/61 40.9
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Recurrent thymomas were mostly considered as “resect-
able” and the strategy of care adopted by all surgical teams 
was based on the assumption that re-do surgery, whenever 
technically feasible, and especially when an R0-resection 
could be achieved, would improve long-term outcomes in 
such patients. Overall, the radical rate of the recurrent tumor 
was substantially acceptable (45/66 cases, nearly 73.7%).
To the best of our knowledge, there are no studies per-
formed in a controlled-randomized fashion that prove surgery 
superior to other approaches in the management of recurrent 
thymoma patients. However, our results—and others before 
us6,8,17,18—have shown that re-resection may indeed prolong 
survival. Actually, after the recurrence of a thymoma, a com-
plete resection is associated with the best chances of sur-
vival6–8 while the role of debulking surgery still remains as 
a forum of open discussion; in our experience, 10-year LTS 
rates are similar when incomplete surgery and chemo/radio-
therapy alone are compared (46.9% versus 46.0%; Table 2).
Focusing our attention on the completeness of resection, 
we report a remarkable 5-year LTS (>80%) in patients treated 
with radical resection, which is significantly higher when 
compared with R+ resections (55%). However, although such 
difference does not reach statistical significance, probably due 
to the limited number of cases, the trend is very interesting. 
Moreover, in agreement with other experiences,7,19,20 the pres-
ence of distant recurrences and incomplete resections was 
proven to be a negative prognostic factor.
Regarding pleural implants as manifestations of recur-
rent thymoma, the treatment remains controversial due to the 
unpredictable natural history of this tumor.16 In such cases, a 
strategy of care based on multimodal treatment (cytoreductive 
surgery followed by hyperthermic intrapleural chemother-
apy or adjuvant chemotherapy) has been proposed and this 
achieved encouraging results.21,22
Our analysis failed to identify any significant differ-
ences in term of outcomes between surgery and chemo/
radiotherapy, even if a positive trend was observed in 
patients with intrathoracic disease treated with surgery with 
respect to patients treated with radio and/or chemotherapy 
alone. However, both the scarcity of data and the significant 
bias of selection in the treatment planning (this resulting 
in different and not entirely comparable cohorts—surgery 
group versus nonsurgical group) suggest caution in drawing 
any definitive conclusion in relation to the best treatment 
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Pertinent literature5 suggested that overall and DFSs after 
thymectomy are affected by Masaoka stage and WHO status. 
Analyzing the distribution of recurrences of the present series 
we may note, in line with other previous studies,6,7,18 that recur-
rences prevail in patients who had Masaoka’s stages III and IV, 
as well as WHO classes A, AB, and B1 (at the moment of thy-
mectomy). Moreover, in patients with type A and AB thymoma, 
there were no tumor-related deaths even after recurrence. This 
data support the results of other authors’ experiences,7,20 who 
very rarely reported tumor recurrences in patients who under-
went radical thymectomy for WHO type A-AB-B1 and in 
Masaoka stage I thymomas, presenting a very good progno-
sis.20 The prognostic value of WHO classification in case of 
thymoma recurrence is matter of discussion. Our study did not 
confirm the potential influence of WHO classification on the 
prognosis of recurrent thymoma patients. In fact, no differ-
ences were found between B2, B3, and C groups.
Interestingly, in this study, an “histological WHO upgrad-
ing” was found in 25 cases (about 40.9%) as reported in Table 1. 
Histological WHO upgrading (usually a migration from initial 
WHO class at thymectomy to WHO class at the moment of treat-
ment of the recurrence) was initially described by Pescarmona et 
al.23 and represents a very debated issue. Indeed, findings similar 
to ours were observed by Ciccone and Rendina24 that reported 
a histological WHO upgrading in about 40% of recurrent thy-
moma patients. The authors speculated—and we are completely 
in line with this assumption—that this phenomenon “may be 
due to the fact that the histology really changes, or to the fact that 
only a minority component within the cortically-differentiated 
primary tumor relapses.” More recently Bae et al.25 reported a 
TABLE 2.  Long-Term Survival after Treatment of Thymic Relapse (Log-Rank Test)
Survival Rate from Recurrence
p5 years 10 years
Overall 68.7 52.0
Gender 0.92
  Male 71.9 53.3
  Female 79.1 50.3
Age
  Over 60 79.1 35.7 0.5
  Under 60 59.1 19.7
WHO histological classification of primary tumor
  A 100 100
  AB 100 100
  B1 40.1 40.1
  B2 76.9 56.8
  B3 68.6 48.0
Myasthenia gravis 0.34
  No MG 62.7 46.0
  MG 72.2 57.3
Resection 0.13
  Incomplete resection 55.9 46.5
  Complete resection 82.4 65.4
Recurrence treatment 0.19
 Surgery 70.2 54.1
 Chemo/RT 64.3 46.9
Histotype upgrading 0.60
  No 74.3 49.9
  Yes 67.0 58.6
WHO histological classification of relapses 0.03
  B1 55.9 33.6
  B2 72.7 52.9
  B3 82.8 72.4
  C 51.4 51.4
Site of first recurrence 0.21
  Mediastinum 83.9 55.9
  Pleural 65.2 56.6
  Lung 68.4 41.3
  Other 40.3 0
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histological WHO upgrading in five cases (among a series of 41 
recurrent thymomas), confirming that the trend in histological 
change occurred in the direction of more aggressive histological 
types. The authors theorized that the histological WHO upgrad-
ing may be attributable to the reduction of lymphocytes and the 
subsequent emphasis of the role of the epithelial components 
after the administration of steroid therapy, being all patients with 
histological WHO upgraded treated with steroids for MG.
In our series, the “histological WHO upgrading” was 
not identified as a relevant prognostic factor, probably dis-
proving the hypothesis that this histological change cor-
relates with a more aggressive behavior. In our opinion, 
this phenomenon may be attributed to the combination of 
both the clinical scenarios described above (only thymic 
cells with cortical differentiation have a potential of recur-
rences, suggested by Ciccone and Rendina24 and histological 
TABLE 3.  Disease-Free Survival from First Recurrence: Log-Rank Test
Disease-Free Survival from Recurrence Disease-Free Survival (R0-resected Patients)
5 years 10 years p 5 years 10 years p
Overall 73.6 48.3
Gender 0.56 0.88
  Male 72.9 55.5 76.3 56.3
  Female 74.2 48.2 82.5 55.8
Masaoka stage 0.75
  I 100 100
  II 87.5 29.2
  III 72.3 51.6
  IV 63.7 37.1
WHO histological classification of primary tumor 0.002 <0.001
  A 100 100 100
  AB 100 100 100 100
  B1 56.9 31.3 40.0 40.0
  B2 79.3 46.3 82.4 41.9
  B3 77.4 66.8 81.8 58.4
Myasthenia gravis 0.25 0.30
  No MG 63.5 39.9 72.7 46.3
  MG 75.0 59.5 78.4 54.9
Recurrence treatment 0.23
  Surgery 100 80.0
  Chemo/RT 60.5 46.4
Completeness of resection 0.03
  R0 78.9 57.2
  R1 55.0 24.4
Recurrence adjuvant treatment 0.58 0.90
  No 41.4 41.4 55.7 55.7
  Chemo/RT 76.2 39.2 83.3 42.9
Histotype upgrading 0.41 0.48
  No 76.0 54.3 74.8 44.4
  Yes 76.4 66.8 82.5 68.8
WHO histological classification of relapses 0.05 0.01
  B1 33.0 0 33.0 —
  B2 68.7 47.1 74.5 55.9
  B3 83.6 46.4 92.9 58.0
  C 60.0 30.0 66.7 66.7
Site of first recurrence 0.04 0.33
  Mediastinum 100 85.7 100 75.0
  Pleural 69.9 48.6 72.8 48.2
  Lung 64.8 51.9 68.6 51.4
  Other 50.0 0.0 100 0
Values <0.05 are reported in italics.
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changes related to steroid treatment, suggested by Bae 
et al).25 Obviously, only further ad hoc evaluations will pos-
sibly clarify this  controversial issue.
It is worth to mention, as a final point of discussion, 
the fact that the site of recurrence reflects the indolent 
nature of these epithelial neoplasms. In this study, the site 
of recurrence does not significantly influence the overall 
LTS but has an impact on the DFS (Fig. 3). Moreover, we 
also observed that the pleural and pulmonary recurrence 
had similar DFS rate. This aspect should not be underes-
timated because pulmonary metastasis could be labeled as 
“locoregional” relapses and, accordingly, not equivalent in 
terms of treatment and prognosis with other hematogenous 
recurrences.
In this setting, the obtaining of a complete resection 
when treating a thymoma recurrence with pleural dissemina-
tion is still a matter of discussion. Theoretically, comparing 
this scenario with pulmonary thymoma metastases (surgically 
resectable), the lung resection could probably ensure the cer-
tainty of a complete resection, while pleurectomy, in case of 
pleural invasion, would indeed not.16
Limitations and Strengths
Our report has the usual limitations of retrospec-
tive studies on rare diseases (the long duration of patients 
inclusion and the limited absolute number of patients). 
Moreover, the fact that data were collected from different 
centers without a centralized path review to choose the best 
treatment strategy (surgical versus non-surgical approach) 
in recurrent thymoma patients represents a further signifi-
cant limitation.
Despite all the limitations mentioned above, this study 
collects a significant cohort (the largest series so far reported 
in the English literature) with a long follow-up data so as to 
perform a comprehensive analysis of the prognostic factors and 
discuss on the clinical and pathological findings at the moment 
of thymic recurrence. In our opinion, this adds new information 
potentially useful to tailor a likely better strategy of care for 
these patients.
CONCLUSION
Thymoma, although an indolent disease, may recur 
(usually as local or pleural relapse) even several years after 
radical thymectomy (mean DFI of nearly 7 years). Overall, 
the LTSs are substantially acceptable (68.7% and 52% at 
5 years and 10 years, respectively). Although not correlated 
with a statistically significant better survival, surgical resec-
tion, where deemed reasonably feasible, could be indicated 
in cases of recurrent thymoma. Indeed, a very rewarding sur-
vival (82.4% and 65.4% at 5 years and 10 years, respectively) 
could be expected when a complete resection of the thymoma 
 recurrence is achieved.
Finally, an histological WHO upgrading (migration 
from low-risk WHO classes at thymectomy to high-risk WHO 
classes at recurrence) may be observed in a remarkable amount 
of patients, but this seems to be not influencing their prognosis.
REFERENCES
 1. National Comprehensive Cancer Network (NCCN) Clinical Practice 
Guidelines in Oncology (NCCN Guidelines) Thymomas and Thymic 
Carcinomas. Version 2.2012, 11/09/11. Available at: www.nccn.org/pro-
fessionals/physician_gls/f_guideline.asp#thymic
 2. Regnard JF, Magdeleinat P, Dromer C, et al. Prognostic factors and long-
term results after thymoma resection: a series of 307 patients. J Thorac 
Cardiovasc Surg 1996;112:376–384.
 3. Maggi G, Casadio C, Cavallo A, Cianci R, Molinatti M, Ruffini E. Thymoma: 
results of 241 operated cases. Ann Thorac Surg 1991;51:152–156.
 4. Margaritora S, Cesario A, Cusumano G, et al. Thirty-five-year follow-up 
analysis of clinical and pathologic outcomes of thymoma surgery. Ann 
Thorac Surg 2010;89:245–252.
 5. Huang J, Detterbeck FC, Wang Z, Loehrer PJ. Standard outcome mea-
sures for thymoma malignancies. J Thorac Oncol 2010;5:2017–2023.
 6. Regnard JF, Zinzindohoue F, Magdeleinat P, Guibert L, Spaggiari L, 
Levasseur P. Results of re-resection for recurrent thymomas. Ann Thorac 
Surg 1997;64:1593–1598.
 7. Margaritora S, Cesario A, Cusumano G, et al. Single-centre 40-year 





Overall Disease-Free  
Survival
Disease-Free Survival  
Complete Resections
Univariate CI p Univariate CI p Univariate CI p
Age 1.02 0.89–1.05 0.24 0.99 0.96–1.03 0.82 1.84 0.49–6.91 0.36
Gender 1.01 0.53–2.13 0.85 1.23 0.60–2.55 0.56 2.05 0.67–6.23 0.20
Surgery 0.56 0.27–1.19 0.13 3.59 0.85–15.2 0.81
Myasthenia gravis 1.14 0.69–2.87 0.33 0.26 0.31–1.35 0.66 3.09 0.91–10.5 0.07
Stage Masaoka 1.13 0.72–1.67 0.64 1.29 0.81–2.04 0.28 1.08 0.48–2.44 0.84
WHO(primary tumor) 1.03 0.67–1.58 0.89 0.67 0.43–1.03 0.07 1.09 0.58–1.74 0.91
WHO (relapse) 0.71 0.37–1.35 0.32 0.71 0.41–1.25 0.23 0.10 0.01–0.74 0.02
Adjuvant therapy 0.35 0.19–1.82 0.36 0.73 0.24–2.22 0.58 0.92 0.24–3.49 0.90
Completeness of resection 0.46 0.16–1.29 0.14 0.39 0.16–0.95 0.04
Site of recurrence 1.25 0.41–1.25 0.41 1.89 1.13–3.13 0.01 2.32 1.13–4.73 0.02
WHO upgrade 1.26 0.51–3.14 0.61 0.65 0.23–1.85 0.42 2.23 0.23–21.03 0.48
Values <0.05 are reported in italics.
1804 Copyright © 2014 by the International Association for the Study of Lung Cancer
Sandri et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 12, December 2014
 8. Ruffini E, Mancuso M, Oliaro A,et al. Recurrence of thymoma: analy-
sis of clinicopathologic features, treatment, and outcome. J Thorac 
Cardiovasc Surg 1997;113:55–63.
 9. Lococo F, Cesario A, Margaritora S, Granone P. Twenty-one-year survival 
in an invasive thymoma successfully treated with seven-fold iterative sur-
gery. Interact Cardiovasc Thorac Surg 2010;11:322–324.
 10. Giaccone G, Wilmink H, Paul MA, van der Valk P. Systemic treatment of 
malignant thymoma: a decade experience at a single institution. Am J Clin 
Oncol 2006;29:336–344.
 11. Loehrer PJ Sr, Kim K, Aisner SC, et al. Cisplatin plus doxorubicin plus 
cyclophosphamide in metastatic or recurrent thymoma. Final results of an 
intergroup trial. J Clin Oncol 1994;12:1164–1168.
 12. Bott M, Wang H, Travis W, et al. Management and outcomes of relapse 
after treatment for thymoma and thymic carcinoma. Ann Thoracic Surg 
2011;92:1984–1991.
 13. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thy-
momas with special reference to their clinical stages. Cancer 1981;48: 
2485–2492.
 14. Rosai J. Histological Typing of Tumors of the Thymus. World Health 
Organization International Histological Classification of Tumors, 2nd ed. 
New York, Berlin: Springer-Verlag, 1999.
 15. Awad WI, Symmans PJ, Dussek JE. Recurrence of stage I thymoma 32 
years after total excision. Ann Thorac Surg 1998;66:2106–2108.
 16. Lucchi M, Basolo F, Mussi A. Surgical treatment of pleural recurrence 
from thymoma. Eur J Cardiothoracic Surg 2008;33:707–711.
 17. Urgesi A, Monetti U, Rossi G, Ricardi U, Maggi G, Sannazzari GL. 
Aggressive treatment of intrathoracic recurrences of thymoma. Radiother 
Oncol 1992;24:221–225.
 18. Okumura M, Shiono H, Inoue M,et al. Outcome of surgical treat-
ment for recurrent thymic epithelial tumors with reference to world 
health organization histologic classification system. J Surg Oncol 
2007;95:40–44.
 19. Haniuda M, Kondo R, Numanami H, Makiuchi A, Machida E, Amano J. 
Recurrence of thymoma: clinicopathological features, re-operation, and 
outcome. J Surg Oncol 2001;78:183–188.
 20. Ströbel P, Bauer A, Puppe B, et al. Tumor recurrence and survival in 
patients treated for thymomas and thymic squamous cell carcinomas: a 
retrospective analysis. J Clin Oncol 2004;22:1501–1509.
 21. Refaely Y, Simansky DA, Paley M, Gottfried M, Yellin A. Resection and 
perfusion thermochemotherapy: a new approach for the treatment of thy-
mic malignancies with pleural spread. Ann Thorac Surg 2001;72:366–370.
 22. Palmieri G, Montella L, Martignetti A, et al. Somatostatin ana-
logs and prednisone in advanced refractory thymic tumors. Cancer 
2002;94:1414–1420.
 23. Pescarmona E, Rendina EA, Venuta F, Ricci C, Baroni CD. Recurrent thymoma: 
evidence for histological progression. Histopathology 1995;27:445–449.
 24. Ciccone AM, Rendina EA. Treatment of recurrent thymic tumors. Semin 
Thorac Cardiovasc Surg. 2005;17(1):27–31.
 25. Bae MK, Byun CS, Lee CY, et al. Clinical outcomes and prognosis of 
recurrent thymoma management. J Thorac Oncol 2012;7:1304–14.
Erratum
Development of the International Thymic Malignancy Interest Group International Database: An Unprecedented Resource for the Study of a Rare Group 
of Tumors: Erratum
The article that appeared on page 1573 of the October 2014 issue of the Journal of Thoracic Oncology contained errors. The paragraph 
under the heading “Treatment” in the Results section should have appeared as follows:
TREATMENT
The vast majority of submitted cases were treated at initial diagnosis with surgery as primary therapy (Fig. 2). Adjuvant radiotherapy was 
administered to 1664 patients (42%), and a minority of patients received neoadjuvant therapy, either chemotherapy (11%) or radiotherapy 
(2%). Less than 1% of cases received palliative chemotherapy (n = 27) or radiotherapy (n = 7) only.
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